Ignite Creation Date:
2024-05-06 @ 7:18 PM
Last Modification Date:
2024-10-26 @ 3:04 PM
Study NCT ID:
NCT05965570
Status:
COMPLETED
Last Update Posted:
2023-12-11
First Post:
2023-07-19
Brief Title:
A Study to Investigate Effect of Clarithromycin a Strong CYP3A4 Inhibitor on Brensocatib Pharmacokinetics in Healthy Participants
Sponsor:
Insmed Incorporated
Organization:
Insmed Incorporated
Study Overview
Official Title:
A Phase 1 Open-label Fixed-sequence Study to Investigate the Effect of Clarithromycin a Strong CYP3A4 Inhibitor on Brensocatib Pharmacokinetics in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to determine the effect of clarithromycin on the single-dose pharmacokinetics PK of brensocatib in healthy participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None